Revolution Medicines CFO sells 35,750 shares

Q: How many RVMD shares did CFO Jack Anders sell?

On November 11, 2026, Jack Anders sold 35,750 common shares in 11 transactions, at reported prices ranging from $181.0421 to $192.8406 per share. Several footnotes describe the reported prices as weighted averages across multiple trades. The transactions were under a Rule 10b5-1 plan adopted August 12, 2026.

Q: What option exercise prices did RVMD CFO Jack Anders report?

On November 11, 2026, Anders exercised options to acquire 15,900 shares at $42.45 per share and 19,850 shares at $18.56 per share. The options were fully vested and had expiration dates of March 4, 2031, and March 1, 2032, respectively.

Available on EDGAR 11/13/2026 - 06:00 PM EST Accepted by SEC EDGAR 11/13/2026 - 06:00 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Financial Officer Jack Anders exercised vested options on November 11, 2026, acquiring 15,900 shares at $42.45 per share and 19,850 shares at $18.56 per share. He also sold 35,750 common shares that day in 11 transactions. Reported sale prices ranged from $181.0421 to $192.8406 per share; footnotes identify several prices as weighted averages across multiple trades.

The transactions were made under a Rule 10b5-1 trading plan adopted August 12, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 35,750 shares ($5.68M approx. pre-tax spread)

Exercise and Sale 15 txns

Insider Anders Jack

Role Chief Financial Officer

Sold 35,750 shs ($6.72M)

Approx. gross sale proceeds $6.72M

Approx. exercise cost $1.04M

Approx. pre-tax spread $5.68M

Share of Position Sold 23.1%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F13}	15,900	$42.45	$675K
Exercise	Stock Option (Right to Buy) ^{F1, F13}	19,850	$18.56	$368K
Exercise	Common Stock ^F1	15,900	$42.45	$675K
Exercise	Common Stock ^F1	19,850	$18.56	$368K
Sale	Common Stock ^{F1, F2}	3,499	$181.0421	$633K
Sale	Common Stock ^{F1, F3}	5,776	$182.0901	$1.05M
Sale	Common Stock ^{F1, F4}	2,700	$182.8704	$494K
Sale	Common Stock ^{F1, F5}	1,900	$184.0246	$350K
Sale	Common Stock ^{F1, F6}	800	$185.0363	$148K
Sale	Common Stock ^{F1, F7}	400	$186.4138	$75K
Sale	Common Stock ^{F1, F8}	600	$187.3371	$112K
Sale	Common Stock ^F1	200	$189.17	$38K
Sale	Common Stock ^{F1, F9}	500	$190.994	$95K
Sale	Common Stock ^{F1, F10}	9,486	$191.9401	$1.82M
Sale	Common Stock ^{F1, F11, F12}	9,889	$192.8406	$1.91M

Holdings After Transaction: Stock Option (Right to Buy) — 750 options (Direct); Common Stock — 119,216 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 36,500 to 750 options (Direct); Common Stock, 119,216 to 119,216 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (13)

F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 12, 2026.
F2. The transaction was executed in multiple trades at prices ranging from $180.50 to $181.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. The transaction was executed in multiple trades at prices ranging from $181.51 to $182.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4. The transaction was executed in multiple trades at prices ranging from $182.56 to $183.51, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5. The transaction was executed in multiple trades at prices ranging from $183.59 to $184.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6. The transaction was executed in multiple trades at prices ranging from $184.59 to $185.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7. The transaction was executed in multiple trades at prices ranging from $185.96 to $186.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F8. The transaction was executed in multiple trades at prices ranging from $186.99 to $187.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F9. The transaction was executed in multiple trades at prices ranging from $190.43 to $191.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F10. The transaction was executed in multiple trades at prices ranging from $191.44 to $192.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F11. The transaction was executed in multiple trades at prices ranging from $192.44 to $193.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F12. Includes 43,650 restricted stock units.
F13. Fully vested.

Key Figures

Shares acquired through option exercise: 15,900 shares Option exercise price: $42.45 per share Shares acquired through option exercise: 19,850 shares +4 more

7 metrics

Shares acquired through option exercise 15,900 shares November 11, 2026; exercise price $42.45 per share

Option exercise price $42.45 per share For options exercised to acquire 15,900 shares on November 11, 2026

Shares acquired through option exercise 19,850 shares November 11, 2026; exercise price $18.56 per share

Option exercise price $18.56 per share For options exercised to acquire 19,850 shares on November 11, 2026

Common shares sold 35,750 shares Across 11 transactions on November 11, 2026

Reported sale price $181.0421 per share 3,499 shares sold on November 11, 2026; weighted average across multiple trades

Reported sale price $192.8406 per share 9,889 shares sold on November 11, 2026; weighted average across multiple trades

Key Terms

Rule 10b5-1 trading plan, weighted average sale price

2 terms

Rule 10b5-1 trading plan regulatory

"transaction made pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"the price reported reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RVMD shares did CFO Jack Anders sell?

On November 11, 2026, Jack Anders sold 35,750 common shares in 11 transactions, at reported prices ranging from $181.0421 to $192.8406 per share. Several footnotes describe the reported prices as weighted averages across multiple trades. The transactions were under a Rule 10b5-1 plan adopted August 12, 2026.

What option exercise prices did RVMD CFO Jack Anders report?

On November 11, 2026, Anders exercised options to acquire 15,900 shares at $42.45 per share and 19,850 shares at $18.56 per share. The options were fully vested and had expiration dates of March 4, 2031, and March 1, 2032, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last)

(First)

(Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/11/2026		M⁽¹⁾		15,900	A	$42.45	135,116	D
Common Stock	11/11/2026		M⁽¹⁾		19,850	A	$18.56	154,966	D
Common Stock	11/11/2026		S⁽¹⁾		3,499	D	$181.0421⁽²⁾	151,467	D
Common Stock	11/11/2026		S⁽¹⁾		5,776	D	$182.0901⁽³⁾	145,691	D
Common Stock	11/11/2026		S⁽¹⁾		2,700	D	$182.8704⁽⁴⁾	142,991	D
Common Stock	11/11/2026		S⁽¹⁾		1,900	D	$184.0246⁽⁵⁾	141,091	D
Common Stock	11/11/2026		S⁽¹⁾		800	D	$185.0363⁽⁶⁾	140,291	D
Common Stock	11/11/2026		S⁽¹⁾		400	D	$186.4138⁽⁷⁾	139,891	D
Common Stock	11/11/2026		S⁽¹⁾		600	D	$187.3371⁽⁸⁾	139,291	D
Common Stock	11/11/2026		S⁽¹⁾		200	D	$189.17	139,091	D
Common Stock	11/11/2026		S⁽¹⁾		500	D	$190.994⁽⁹⁾	138,591	D
Common Stock	11/11/2026		S⁽¹⁾		9,486	D	$191.9401⁽¹⁰⁾	129,105	D
Common Stock	11/11/2026		S⁽¹⁾		9,889	D	$192.8406⁽¹¹⁾	119,216⁽¹²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$42.45	11/11/2026		M⁽¹⁾			15,900	⁽¹³⁾	03/04/2031	Common Stock	15,900	$42.45	0	D
Stock Option (Right to Buy)	$18.56	11/11/2026		M⁽¹⁾			19,850	⁽¹³⁾	03/01/2032	Common Stock	19,850	$18.56	750	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 12, 2026.

2. The transaction was executed in multiple trades at prices ranging from $180.50 to $181.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transaction was executed in multiple trades at prices ranging from $181.51 to $182.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The transaction was executed in multiple trades at prices ranging from $182.56 to $183.51, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. The transaction was executed in multiple trades at prices ranging from $183.59 to $184.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

6. The transaction was executed in multiple trades at prices ranging from $184.59 to $185.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

7. The transaction was executed in multiple trades at prices ranging from $185.96 to $186.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

8. The transaction was executed in multiple trades at prices ranging from $186.99 to $187.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

9. The transaction was executed in multiple trades at prices ranging from $190.43 to $191.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

10. The transaction was executed in multiple trades at prices ranging from $191.44 to $192.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

11. The transaction was executed in multiple trades at prices ranging from $192.44 to $193.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

12. Includes 43,650 restricted stock units.

13. Fully vested.

	/s/ Jack Anders	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR